Literature DB >> 9369956

Human cystatin C forms an inactive dimer during intracellular trafficking in transfected CHO cells.

G S Merz1, E Benedikz, V Schwenk, T E Johansen, L K Vogel, J I Rushbrook, H M Wisniewski.   

Abstract

To define the cellular processing of human cystatin C as well as to lay the groundwork for investigating its contribution to lcelandic Hereditary Cerebral Hemorrhage with Amyloidosis (HCHWA-I), we have characterized the trafficking, secretion, and extracellular fate of human cystatin C in transfected Chinese hamster ovary (CHO) cells. It is constitutively secreted with an intracellular half-life of 72 min. Gel filtration of cell lysates revealed the presence of three cystatin C immunoreactive species; an 11 kDa species corresponding to monomeric cystatin C, a 33 kDa complex that is most likely dimeric cystatin C and immunoreactive material, > or = 70 kDa, whose composition is unknown. Intracellular monomeric cystatin C is functionally active as a cysteine protease inhibitor, while the dimer is not. Medium from the transfected CHO cells contained only active monomeric cystatin C indicating that the cystatin C dimer, formed during intracellular trafficking, is converted to monomer at or before secretion. Cells in which exit from the endoplasmic reticulum (ER) was blocked with brefeldin A contained the 33 kDa species, indicating that cystatin C dimerization occurs in the ER. After removal of brefeldin A, there was a large increase in intracellular monomer suggesting that dimer dissociation occurs later in the secretion pathway, after exiting the ER but prior to release from the cell. Extracellular monomeric cystatin C was found to be internalized into lysosomes where it again dimerized, presumably as a consequence of the low pH of late endosome/lysosomes. As a dimer, cystatin C would be prevented from inhibiting the lysosomal cysteine proteases. These results reveal a novel mechanism, transient dimerization, by which cystatin C is inactivated during the early part of its trafficking through the secretory pathway and then reactivated prior to secretion. Similarly, its uptake by the cell also leads to its redimerization in the lysosomal pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369956     DOI: 10.1002/(SICI)1097-4652(199712)173:3<423::AID-JCP15>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  20 in total

1.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms.

Authors:  G P Shi; G K Sukhova; A Grubb; A Ducharme; L H Rhode; R T Lee; P M Ridker; P Libby; H A Chapman
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration.

Authors:  Enric Vilar; Capella Boltiador; Adie Viljoen; Ashwini Machado; Ken Farrington
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 8.237

3.  Crystal structure of 12-oxophytodienoate reductase 3 from tomato: self-inhibition by dimerization.

Authors:  Constanze Breithaupt; Robert Kurzbauer; Hauke Lilie; Andreas Schaller; Jochen Strassner; Robert Huber; Peter Macheroux; Tim Clausen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

4.  Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.

Authors:  Catera L Wilder; Charlene Walton; Valencia Watson; Fermin A A Stewart; Jade Johnson; Shelly R Peyton; Christine K Payne; Valerie Odero-Marah; Manu O Platt
Journal:  Int J Biochem Cell Biol       Date:  2016-08-31       Impact factor: 5.085

5.  A mechanistic model to predict effects of cathepsin B and cystatin C on β-amyloid aggregation and degradation.

Authors:  Tyler J Perlenfein; Regina M Murphy
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

6.  Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system.

Authors:  Yuekang Xu; Petra Lindemann; Javier Vega-Ramos; Jian-Guo Zhang; Jose A Villadangos
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 7.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

Review 8.  Endothelial cells and cathepsins: Biochemical and biomechanical regulation.

Authors:  Manu O Platt; W Andrew Shockey
Journal:  Biochimie       Date:  2015-10-13       Impact factor: 4.079

9.  Influence of point mutations on the stability, dimerization, and oligomerization of human cystatin C and its L68Q variant.

Authors:  Aneta Szymańska; Elżbieta Jankowska; Marta Orlikowska; Izabela Behrendt; Paulina Czaplewska; Sylwia Rodziewicz-Motowidło
Journal:  Front Mol Neurosci       Date:  2012-07-27       Impact factor: 5.639

10.  Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis.

Authors:  P Strojan; I Oblak; B Svetic; L Smid; J Kos
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.